Unraveling Cancer Pain Dynamics (Yale)
The goal of this initiative is to provide education to clinicians, involved in the assessment and management of cancer pain in adult patients, on the appropriate and safe use of opioid analgesics, optimizing non-opioid analgesics and adjuvant medications, and integrating non-pharmacological appro
Category
  • Pain
  • Palliative Care
  • Supportive Care Topics
Format
  • Live Webinar
Credits
  • 4.00 AAPA Category 1 CME credit
  • 4.00 ACPE contact hours
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 ANCC contact hours
  • 4.00 ASWB continuing education credit
  • 4.00 Participation
Unraveling Cancer Pain Dynamics (UColorado)
The goal of this initiative is to provide education to clinicians, involved in the assessment and management of cancer pain in adult patients, on the appropriate and safe use of opioid analgesics, optimizing non-opioid analgesics and adjuvant medications, and integrating non-pharmacological appro
Category
  • Pain
  • Palliative Care
  • Supportive Care Topics
Format
  • Live Webinar
Credits
  • 4.00 AAPA Category 1 CME credit
  • 4.00 ACPE contact hours
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 ANCC contact hours
  • 4.00 ASWB continuing education credit
  • 4.00 Participation
NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Category
  • Gastric/Esophageal Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date October 21, 2024
NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.
Category
  • Breast Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date October 29, 2024
NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.
Category
  • Lung Cancers
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date November 6, 2024
NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers
Despite advances in radiation therapy (RT) techniques for the treatment of head and neck cancers, patients with head and neck cancers continue to be at risk of oral and dental complications after surgery or RT because of treatment-induced xerostomia and salivary gland dysfunction, which are associated with increased dental caries.
Category
  • Head and Neck Cancers
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date November 14, 2024
NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Category
  • Bladder Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date November 15, 2024
NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia
Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.
Category
  • Acute Myelogenous Leukemia
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date November 20, 2024